ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 631

Usefulness of the Minimally-Invasive Minor Salivary Gland Biopsy in Patients Presenting with Sicca Syndrome: Prospective Evaluation of 200 Patients

Soledad Retamozo1, Pilar Brito-Zerón1, Albert Bové2, Hoda Gheitasi2, Courtney Grant3, Daphne Superville4, Belchin Kostov5, Antoni Sisó-Almirall5, Llucia Alós6 and Manuel Ramos-Casals1, 1Department of Autoimmune Diseases, CELLEX-IDIBAPS, Hospital Clínic, Barcelona, Barcelona, Spain, 2Department of Autoimmune Diseases, IDIBAPS, Hospital Clínic, Barcelona, Spain, 3University of Glasgow, Glasgow, United Kingdom, 4Massachusetts Institute of Technology (MIT), Cambridge, MA, 5Primary Care Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Primary Care Centre Les Corts, CAPSBE, Barcelona, Spain, 6Department of Pathology, Hospital Clínic, Barcelona, Spain

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Sjögren's Syndrome Poster I: Clinical Insights into Sjögren's Syndrome

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Sicca syndrome is a clinical presentation that is common for several systemic diseases that may infiltrate the exocrine glands. The most frequent disease is Sjögren’s syndrome (SS), but other systemic diseases such as sarcoidosis, amyloidosis of IgG4-related disease may also infiltrate salivary glands. We analyzed the safety and usefulness of a new diagnostic tool for investigating minor salivary glands (minimally-invasive biopsy technique) in patients presenting with sicca syndrome.

Methods:

We present a prospective analysis of 200 patients presenting with sicca syndrome (defined by the presence of xerostomia and xerophthalmia, with positive results for ocular tests and/or parotid scintigraphy) in whom a minimally-invasive biopsy of minor salivary glands was carried out at a single center. For all biopsy samples, a cumulative focus score of lymphoplasmacytic infiltration was evaluated (Chisholm Mason score, CMs), together with investigation of other infiltrative processes caused by granuloma, amyloid, lipids or IgG4-positive cells.

Results:

All biopsies but two disclosed salivary gland tissue. Only 28 patients (14%) reported transient adverse events recovered completely during the first 24h. Histopathological diagnosis was available in 189 cases (158 women, 31 men, mean age 59 years): 44% of patients showed a non-specific chronic sialoadenitis (NSCS) (CMs=1-2), 21% focal lymphocytic sialoadenitis (FLS) suggestive of primary Sjögren syndrome (CMs=3-4), 12% chronic atrophic sialadenitis (CAS) (CMs unclassifiable), 18% normal glandular tissue (CMs=0) and other diagnosis in the remaining 4% (1 case of amyloidosis, 1 of sarcoidosis, 6 of lipoid infiltration and 1 salivary oncocytic cystadenoma); no patient had IgG4-related disease. The higher mean age was found in patients with CAS (69 years), followed by those with NSCS (59 years), those with FLS (57 years) and those with a normal result (54 years) (p<0.001). A higher frequency of FLS was found in patients with positive immunological markers including RF, anti-Ro, anti-La, hypocomplementemia and cryoglobulins (p<0.05). The percentage of patients diagnosed with Sjögren syndrome varied according to the concomitant systemic features: 13% of patients presenting with an isolated sicca syndrome had FLS in comparison with 32% of those who present with extraglandular involvement (p<0.05).

 Conclusion:

We found sialoadenitis in nearly 80% of patients presenting with sicca syndrome. One quarter of these patients were diagnosed with Sjögren syndrome (focal lymphocytic sialadenitis). An older age was associated with a higher frequency of atrophic and chronic histopathological findings, while the presence of systemic features was associated with a higher frequency of focal lymphocytic sialadenitis. Only 1% of patients showed other systemic infiltrative diseases (one case of sarcoidosis, one of amyloidosis); no patient showed infiltration by IgG4+ cells.


Disclosure: S. Retamozo, None; P. Brito-Zerón, None; A. Bové, None; H. Gheitasi, None; C. Grant, None; D. Superville, None; B. Kostov, None; A. Sisó-Almirall, None; L. Alós, None; M. Ramos-Casals, Bristol-Myers Squibb, 2.

To cite this abstract in AMA style:

Retamozo S, Brito-Zerón P, Bové A, Gheitasi H, Grant C, Superville D, Kostov B, Sisó-Almirall A, Alós L, Ramos-Casals M. Usefulness of the Minimally-Invasive Minor Salivary Gland Biopsy in Patients Presenting with Sicca Syndrome: Prospective Evaluation of 200 Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/usefulness-of-the-minimally-invasive-minor-salivary-gland-biopsy-in-patients-presenting-with-sicca-syndrome-prospective-evaluation-of-200-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/usefulness-of-the-minimally-invasive-minor-salivary-gland-biopsy-in-patients-presenting-with-sicca-syndrome-prospective-evaluation-of-200-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology